[Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions]. / Pathologie dysimmunitaire de la jonction neuro-musculaire : le syndrome de Lambert-Eaton.
Bull Acad Natl Med
; 198(2): 243-54; discussion 255, 2014 Feb.
Article
em Fr
| MEDLINE
| ID: mdl-26263702
ABSTRACT
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder affecting neuromuscular junctions. LEMS has served as a model of paraneoplastic neurological syndromes and antitumoral immunity, shedding light on the pathological role of autoantibodies directed against synaptic targets. Autoantibodies associated with LEMS are directed against voltage-gated calcium channels (VGCC) present on nerve terminals of neuromuscular synapses. Anti-VGGC antibodies play a direct pathological role in LEMS by blocking VGCC and calcium entry during depolarisation. Nearly half of patients with LEMS have small-cell lung cancer (SCLC), which also expresses VGCC. Diagnosis of LEMS frequently permits early detection and treatment of SCLC Knowledge of this syndrome has led to the discovery of a broad range of cancerous and non cancerous antibody-mediated neurological syndromes, and led to the concept of autoimmune synaptopathies.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Autoanticorpos
/
Doenças Autoimunes
/
Síndrome Miastênica de Lambert-Eaton
/
Junção Neuromuscular
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Limite:
Animals
/
Humans
Idioma:
Fr
Ano de publicação:
2014
Tipo de documento:
Article